249P A phase I/II study of RC148 (PD-1/VEGF bispecific antibody) monotherapy or in combination with docetaxel for the treatment of first- or second-line locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) without actionable genomic

RC148 is an innovative bispecific antibody targeting both PD-1 and vascular endothelial growth factor (VEGF). Dual targeting of PD-1 and VEGF combines two complementary modalities, aiming to improve anti-tumor effects by inhibiting PD-1-mediated immunosuppression and blocking tumor angiogenesis in the tumor microenvironment. This study aimed to evaluate the efficacy and safety of RC148 monotherapy and in combination with docetacel in patients (pts) with la/m NSCLC.

Authors

Institutions

Publication Details

Journal
Immuno-Oncology Technology
Published
2025-12-01
DOI
https://doi.org/10.1016/j.iotech.2025.101448
Primary Topic
Angiogenesis and VEGF in Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

249P A phase I/II study of RC148 (PD-1/VEGF bispecific antibody) monotherapy or in combination with docetaxel for the treatment of first- or second-line locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) without actionable genomic

B. Li, Y. Zhang, Y. Sun, J. Li et al.
Immuno-Oncology Technology
Angiogenesis and VEGF in Cancer
article

249P A phase I/II study of RC148 (PD-1/VEGF bispecific antibody) monotherapy or in combination with docetaxel for the treatment of first- or second-line locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) without actionable genomic

B. Li, Y. Zhang, Y. Sun, J. Li, M. Zhuo, J. Yu, J. Fang, X. Lu, D. Gao, M. Sun, Z. He, S. Huang, Y. Fan, X. Li, Q. Wang, X. Song, Q. Wen, R. Yang, Y. Yu, W. Zheng
article en

Abstract

RC148 is an innovative bispecific antibody targeting both PD-1 and vascular endothelial growth factor (VEGF). Dual targeting of PD-1 and VEGF combines two complementary modalities, aiming to improve anti-tumor effects by inhibiting PD-1-mediated immunosuppression and blocking tumor angiogenesis in the tumor microenvironment. This study aimed to evaluate the efficacy and safety of RC148 monotherapy and in combination with docetacel in patients (pts) with la/m NSCLC.

Immuno-Oncology TechnologyVol. 28
Tongji University (CN), Harbin Medical University (CN), Guilin Medical University (CN), Capital Medical University (CN), Yantai University (CN), Peking University (CN), Kunming Medical University (CN), Peking University Cancer Hospital (CN), Zhejiang Cancer Hospital (CN), Shandong Tumor Hospital (CN), Shanxi Provincial Cancer Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), Jinan Central Hospital (CN), Yantai Academy of Agricultural Sciences (CN), Nanyang Institute of Technology (CN), Hunan Cancer Hospital (CN), Sichuan Cancer Hospital (CN), Fujian Provincial Cancer Hospital (CN), First Affiliated Hospital of Zhengzhou University (CN), Shandong First Medical University (CN), China Medical University (CN)
Good health and well-being
Openalex Percentile: Top 36%
Angiogenesis and VEGF in Cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.